These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 11881743)

  • 1. Huntington's disease: new hope for therapeutics.
    McMurray CT
    Trends Neurosci; 2001 Nov; 24(11 Suppl):S32-8. PubMed ID: 11881743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.
    Jimenez-Sanchez M; Licitra F; Underwood BR; Rubinsztein DC
    Cold Spring Harb Perspect Med; 2017 Jul; 7(7):. PubMed ID: 27940602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder.
    Haque NS; Borghesani P; Isacson O
    Mol Med Today; 1997 Apr; 3(4):175-83. PubMed ID: 9134531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetics and neuropathology of Huntington's disease.
    Reiner A; Dragatsis I; Dietrich P
    Int Rev Neurobiol; 2011; 98():325-72. PubMed ID: 21907094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huntington's disease: from pathology and genetics to potential therapies.
    Imarisio S; Carmichael J; Korolchuk V; Chen CW; Saiki S; Rose C; Krishna G; Davies JE; Ttofi E; Underwood BR; Rubinsztein DC
    Biochem J; 2008 Jun; 412(2):191-209. PubMed ID: 18466116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
    Pfister EL; Kennington L; Straubhaar J; Wagh S; Liu W; DiFiglia M; Landwehrmeyer B; Vonsattel JP; Zamore PD; Aronin N
    Curr Biol; 2009 May; 19(9):774-8. PubMed ID: 19361997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of novel therapies for Huntington's disease: hope and challenge.
    Qin ZH; Wang J; Gu ZL
    Acta Pharmacol Sin; 2005 Feb; 26(2):129-42. PubMed ID: 15663888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How does the Huntington's disease mutation damage cells?
    Rubinsztein DC
    Sci Aging Knowledge Environ; 2003 Sep; 2003(37):PE26. PubMed ID: 13679594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
    Truant R; Atwal RS; Burtnik A
    Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH; Qin ZH
    Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
    Kenney C; Powell S; Jankovic J
    Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huntington's disease: clinical presentation and treatment.
    Novak MJ; Tabrizi SJ
    Int Rev Neurobiol; 2011; 98():297-323. PubMed ID: 21907093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms and potential therapeutical targets in Huntington's disease.
    Zuccato C; Valenza M; Cattaneo E
    Physiol Rev; 2010 Jul; 90(3):905-81. PubMed ID: 20664076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanisms of neuronal death in Huntington's disease. First part: general considerations and histopathological features].
    Bantubungi K; Blum D
    Rev Med Brux; 2007; 28(5):413-21. PubMed ID: 18069515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental models of HD and reflection on therapeutic strategies.
    Kim J; Bordiuk OL; Ferrante RJ
    Int Rev Neurobiol; 2011; 98():419-81. PubMed ID: 21907096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
    Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
    Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic?
    Rangone H; Humbert S; Saudou F
    Pathol Biol (Paris); 2004 Jul; 52(6):338-42. PubMed ID: 15261377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntington's disease.
    MacDonald ME; Gines S; Gusella JF; Wheeler VC
    Neuromolecular Med; 2003; 4(1-2):7-20. PubMed ID: 14528049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.